A challenge You are passionate about providing an intervention (drug or device) to a group of patients who can’t access the current options due to availability or pricing. You could could go the philanthropic route to pay for the interventions. You could work towards regulation to apply downward pressure on pricing. No matter what, you have to
Biotech venture funding metrics continue at historic highs, highlighting that the robust financing environment in the public markets continues to fuel the private markets as well. – Bruce Booth, partner Atlas Venture in Data Snapshot: Venture-Backed Biotech Financing Riding High, April 2015 Here in Madison, Wisconsin, you might not know that was true if you
Alternative title: Pitching a VC on Disruption of Blood Testing You may have seen some recent editorials about the necessary frequency of blood tests for healthy individuals, many of them prompted by a series of tweets from Mark Cuban: Although there are certainly potential dangers in expecting any and all test results to be immediately
This semester I’ve embarked on an adventure to co-teach a class in the University of Wisconsin-Madison Masters in Biotechnology program. What sold me on the experience was the majority of my responsibility is interacting with second year students on their final major project (essentially their thesis). That said, I will give one lecture, which will be “health
Ethan Perlstein, founder of Perlstein Lab, asked a question on Twitter and got some great answers from David Grainger, partner at Index Ventures and Katrine Bosley, CEO of Editas Medicine. (You can read the whole thread by clicking through.) @LifeSciVC @sciencescanner @ksbosley @scientre what's the burn rate distribution of biotech NewCos in for the first year of
I want to share three themes that struck me from the Dohmen Life Science Services Entrepreneur Summit in Milwaukee this week. Is there an age or stage of company that doesn’t require innovation? Dohmen started as an apothecary in 1858 and is a private fifth generation company, which has reinvented itself over the last few years.
Pharma/Biotech Business Model Innovation When I hear/read about business model innovation in pharma/biotech, the themes generally focus on changes that would improve R&D productivity – moving discoveries from academia to industry more efficiently (some examples of university-related incubators), reproducibility of experiments, venture capital firms creating their own early stage companies, pharma moving R&D innovation external (corporate, biotech and
Yesterday on Twitter I asked the following question and I wanted to follow up because it is an interesting topic. Flip but serious: what is lean startup/incubator/hacker version of a university lab? There is a lot of discussion about funding sources for science/biotechnology as pressure increases on some of the traditional pools of money. Yesterday David Shaywitz shared
In a post in March, I suggested that I would represent the “less glamorous side of things” in the biotech industry. This week gave me an opportunity to attempt that directly. Setting the Stage Earlier this year, Bruce Booth at Atlas Venture started a new thing – a great thing: having management from their biotech portfolio companies
There were a few long reads that I’ll be re-reading over the weekend, including: New blood (at Fortune, by Roger Parloff @rparloff) This article profiles the blood diagnostics company, Theranos, and the founder, Elizabeth Holmes. While you will find the founder description interesting, I found myself drawn to the questions of business model, trade secrets and regulation.